U.S. markets close in 3 hours 55 minutes

Mind Medicine (MindMed) Inc. (MMED.NE)

NEO - NEO Real Time Price. Currency in CAD
Add to watchlist
0.7900+0.1100 (+16.18%)
As of 12:05PM EDT. Market open.
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.6800
Open0.7100
Bid0.7900 x N/A
Ask0.7900 x N/A
Day's Range0.7000 - 0.8000
52 Week Range0.2400 - 0.9900
Volume3,330,882
Avg. Volume678,045
Market Cap221.751M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-0.0900
Earnings DateMay 14, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • MindMed and Liechti Lab Announce R&D Collaboration On Psilocybin
      CNW Group

      MindMed and Liechti Lab Announce R&D Collaboration On Psilocybin

      MindMed Collaborating On Study Comparing Effects Induced By LSD and Psilocybin Under Exclusive License Agreement With University Hospital Basel Liechti Lab BASEL, Switzerland, Sept. 24, 2020 /CNW/ -- Mind Medicine (MindMed) Inc.

    • MindMed Confirms No Material Change
      PR Newswire

      MindMed Confirms No Material Change

      Mind Medicine (MindMed) Inc. (NEO: MMED)(OTCQB: MMEDF), the leading neuro-pharmaceutical company for psychedelic inspired medicines announces, at the request of IIROC on behalf of the NEO Exchange, that MindMed's management is unaware of any material change in MindMed's operations that would account for the recent increase in market activity.

    • MindMed Submits Application For NASDAQ Up-Listing, Appoints Canaccord Genuity As Financial Advisor
      PR Newswire

      MindMed Submits Application For NASDAQ Up-Listing, Appoints Canaccord Genuity As Financial Advisor

      Mind Medicine (MindMed) Inc. (NEO: MMED)(OTCQB: MMEDF)(DE: MMQ), the leading drug development company for psychedelic inspired medicines, is evaluating an expanded United States investor base through an up-listing on the NASDAQ Capital Market ("NASDAQ").